RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
  Bone Cancer
  Breast Cancer
  Cervical Cancer
  Gastric Cancer
  Liver Cancer
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Testicular Cancer
 Clinical Trials
 Infectious Diseases
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Oct 11, 2012 - 10:22:56 PM
Endometrial Channel

subscribe to Endometrial newsletter
Latest Research : Cancer : Endometrial

   EMAIL   |   PRINT
Broadening treatment to battle recurrence of endometrial cancer

Jan 17, 2005 - 12:39:00 PM

[RxPG] Mayo Clinic researchers studying endometrial cancer have found that patients at risk for relapse based on identified risk factors had a 46 percent probability of experiencing recurrence within five years despite treatment with state-of-the-art therapy.

The study's findings are important for women deemed at risk because they might need additional treatment, which physicians should consider in their treatment plans for their patients, says Karl Podratz, M.D., Ph.D., the study's lead researcher.

The risk factors the researchers identified were specific characteristics of tissues that had been removed during surgery and were analyzed by microscope. Researchers also said risk factors included whether the tumors were confined to the uterus or if the disease had spread outside the uterus.

In the United States, endometrial cancer is the most common malignancy of the female reproductive tract. Only breast, colon and lung cancers are more prevalent in women. During 2004, it was estimated 40,320 new cases of endometrial cancer would be diagnosed in the United States and 7,090 women would die from the disease.

The study looked at 1,109 patients with endometrial cancer who had surgical treatment at Mayo Clinic in Rochester from 1984 to 1996. Based on data from their medical records, 915 patients with endometrial cancer met the following criteria to be included in the study: treatment included hysterectomy, and no other malignancy was diagnosed within five years before or after the diagnosis of endometrial cancer.

"The 46 percent recurrence rate for the at-risk patients among the expected cases of newly diagnosed endometrial cancer in 2004 is close to the number of deaths the disease is expected to cause in that period," says Dr. Podratz. "We feel that to maximize outcomes, approximately one-third of the patients with endometrial cancer in the United States, or about 14,000 women, would potentially benefit from enrollment in clinical trials addressing the new target-based therapeutic approach."

The new approach for treatment would be based on the inclusion of risk factors identified in previous studies and categorization of patients according to their risks for different patterns of recurrence, such as in the lungs, abdomen or lymph nodes. In doing this, physicians would be able to better predict and focus treatments on anticipated routes of the disease and its relapse.

Publication: Mayo Clinic
On the web: The findings of this study were reported in the October 2004 issue of the medical journal Gynecologic Oncology, (www.sciencedirect.com/science/journal/00908258). 

Advertise in this space for $10 per month. Contact us today.

Related Endometrial News
New technique to detect cancer in early stages
Adjuvant radiotherapy improves survival in Stage I Endometrial Cancer
Raloxifene May Protect Against Endometrial Cancer
Cancer Risk Highest in Combined HRT
Broadening treatment to battle recurrence of endometrial cancer

Subscribe to Endometrial Newsletter

Enter your email address:

For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online



    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)